Insulin

Insulin like Growth Factor 1 Receptor IGF 1R

Although the insulin-like growth factor-1 receptor (IGF-1R) was first cloned in 1986, it was the success of targeted drugs such as trastuzumab and imatinib that tyrosine kinase inhibitors and growth...

Insulin aspart rDNA

Insulin rDNA Novo

Insulin rDNA Lilly

Sitagliptin may edge glipizide in diabetics with kidney disease

NEW YORK (Reuters Health) - Type 2 diabetics with renal insufficiency had less hypoglycemia with sitagliptin than with glipizide in a recent trial.

Metformin Superior to Glipizide in Diabetics With CAD

Over a median follow-up of five years, treatment with metformin reduced the primary composite end point of death from cardiovascular causes, death from any cause, nonfatal MI, nonfatal stroke, and art...

Germany says Komboglyze has 'no additional benefit'

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that Type II diabetes drug Komboglyze saxagliptin/metformin from Bristol-Myers Squibb Co....

IQWiG rebuffs Forxiga

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) said in a preliminary benefit assessment that Type II diabetes drug Forxiga dapagliflozin from Bristol-Myers Squibb Co. (NYSE:BMY)...

FDA delays decision on Novo's insulin products

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said FDA extended the PDUFA date by three months for NDAs for insulin Degludec and insulin Degludec/insulin aspart to treat Type I and II diabetes. The new date is...

FDA to discuss Novo's insulin products

FDA confirmed the Nov. 8 meeting date for the Endocrinologic and Metabolic Drugs Advisory Committee to discuss NDAs from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) for insulin Degludec and insulin Degludec/...

Lyxumia(R) (lixisenatide) in Combination With Basal Insulin Plus Oral Anti-Diabetics ...

Lixisenatide With Basal Insulin Helped Type 2 Diabetes Patients With Uncontrolled HbA1c Achieve Target Blood Glucose Levels; Lixisenatide Marketing Authorization Application Submitted to Euro...

Lyxumia® (lixisenatide) in Combination with Basal Insulin plus Oral Anti-Diabetics ...

Lixisenatide with basal insulin helped type 2 diabetes patients with uncontrolled HbA1c achieve target blood glucose levels - Lixisenatide marketing authorization application submitted to Eur...

Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.

Purpose The case of a patient with type 2 diabetes mellitus who received combination exenatide-sitagliptin with glipizide is reported. Summary A 55-year-old, 204-lb Caucasian woman arrived at a clinic...

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.

Aim:  To assess the efficacy and safety of saxagliptin vs. glipizide as add-on therapy to metformin in patients with type 2 diabetes mellitus and inadequate glycaemic control on metformin alone. Met...

Dual coating of swellable and rupturable polymers on Glipizide loaded MCC pellets for pulsatile delivery: Formulation design and in vitro evaluation.

This study is aimed to develop and evaluate time dependent rupturable multiparticulate pulsatile delivery system for Glipizide. Microcrystalline cellulose (MCC) based pellets containing Glipizide were...

Saponins from the traditional medicinal plant Momordica charantia stimulate insulin secretion in vitro.

The antidiabetic activity of Momordica charantia (L.), Cucurbitaceae, a widely-used treatment for diabetes in a number of traditional medicine systems, was investigated in vitro. Antidiabetic activity...

GLULISINE VERSUS HUMAN REGULAR INSULIN IN COMBINATION WITH GLARGINE IN NON-CRITICALLY ILL HOSPITALIZED PATIENTS WITH TYPE 2 DIABETES: A RANDOMIZED DOUBLE-BLIND STUDY.

AbstractObjective - To compare the efficacy and safety of the rapid-acting insulin analog glulisine and regular insulin in hyperglycemic hospitalized patients. Research Design and Methods - One-hundre...